Depression after myocardial infarction: TNF-α-induced alterations of the blood-brain barrier and its putative therapeutic implications

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 4, 2013, Pages 561-572

  Liu, Hui ^a,b   Luiten, Paul G M ^a   Eisel, Uli L M ^a   Dejongste, Mike J L ^c   Schoemaker, Regien G ^a,c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b WUHAN UNIVERSITY   (China)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Blood brain barrier; Depression; Myocardial infarction; Neuroinflammation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; CELECOXIB; CITALOPRAM; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ETANERCEPT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; METHYLPREDNISOLONE; MIRTAZAPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE HEART INFARCTION; ADRENERGIC SYSTEM; BLOOD BRAIN BARRIER; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; COMORBIDITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEPRESSION; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ENZYME SPECIFICITY; EXTRACELLULAR MATRIX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNE RESPONSE; INFLAMMATION; LOW DRUG DOSE; MAJOR DEPRESSION; MEMBRANE PERMEABILITY; MENTAL DISEASE; MONOCYTE; NERVOUS SYSTEM INFLAMMATION; NEUROTRANSMISSION; NEUTROPHIL; NONHUMAN; OSTEOARTHRITIS; PARAVENTRICULAR THALAMIC NUCLEUS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PSORIASIS; QUALITY OF LIFE; REVIEW; SHORT COURSE THERAPY; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS; BLOOD-BRAIN BARRIER; DEPRESSION; HUMANS; IMMUNITY; INFLAMMATION; MYOCARDIAL INFARCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875321111     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.02.004     Document Type: Review

References (171)

1. Abbott N.J. Inflammatory mediators and modulation of blood-brain barrier permeability. Cellular and Molecular Neurobiology 2000, 20:131-147.
2. Abraham C.S., Deli M.A., Joo F., Megyeri P., Torpier G. Intracarotid tumor necrosis factor-alpha administration increases the blood-brain barrier permeability in cerebral cortex of the newborn pig: quantitative aspects of double-labelling studies and confocal laser scanning analysis. Neuroscience Letters 1996, 208:85-88.
3. Adamek A., Hu K., Bayer B., Wagner H., Ertl G., Bauersachs J., Frantz S. High dose aspirin and left ventricular remodeling after myocardial infarction: aspirin and myocardial infarction. Basic Research in Cardiology 2007, 102:334-340.
4. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., Mohebbi-Rasa S., Raznahan M., Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depression and Anxiety 2009, 26:607-611.
5. Almeida J.R., Alves T.C., Wajngarten M., Rays J., Castro C.C., Cordeiro Q., Telles R.M., Fraguas R.J., Busatto G.F. Late-life depression, heart failure and frontal white matter hyperintensity: a structural magnetic resonance imaging study. Brazilian Journal of Medical and Biological Research 2005, 38:431-436.
6. Anderson J.L., Adams C.D., Antman E.M., Bridges C.R., Califf R.M., Casey D.E., Chavey W.E., Fesmire F.M., Hochman J.S., Levin T.N., Lincoff A.M., Peterson E.D., Theroux P., Wenger N.K., Wright R.S., Smith S.C., Jacobs A.K., Halperin J.L., Hunt S.A., Krumholz H.M., Kushner F.G., Lytle B.W., Nishimura R., Ornato J.P., Page R.L., Riegel B. American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction), American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Academic Emergency Medicine, ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007, 116:e148-e304.
7. Anthony D.C., Bolton S.J., Fearn S., Perry V.H. Age-related effects of interleukin-1 beta on polymorphonuclear neutrophil-dependent increases in blood-brain barrier permeability in rats. Brain 1997, 120(Pt 3):435-444.
8. Antman E.M., Anbe D.T., Armstrong P.W., Bates E.R., Green L.A., Hand M., Hochman J.S., Krumholz H.M., Kushner F.G., Lamas G.A., Mullany C.J., Ornato J.P., Pearle D.L., Sloan M.A., Smith S.C., Alpert J.S., Anderson J.L., Faxon D.P., Fuster V., Gibbons R.J., Gregoratos G., Halperin J.L., Hiratzka L.F., Hunt S.A., Jacobs A.K., Ornato J.P. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). Journal of the American College of Cardiology 2004, 44:E1-E211.
9. Badoer E. Hypothalamic paraventricular nucleus and cardiovascular regulation. Clinical and Experimental Pharmacology and Physiology 2001, 28:95-99.
10. Berry M.F., Woo Y.J., Pirolli T.J., Bish L.T., Moise M.A., Burdick J.W., Morine K.J., Jayasankar V., Gardner T.J., Sweeney H.L. Administration of a tumor necrosis factor inhibitor at the time of myocardial infarction attenuates subsequent ventricular remodeling. Journal of Heart and Lung Transplantation 2004, 23:1061-1068.
11. Bodi V., Sanchis J., Nunez J., Mainar L., Minana G., Benet I., Solano C., Chorro F.J., Llacer A. Uncontrolled immune response in acute myocardial infarction: unraveling the thread. American Heart Journal 2008, 156:1065-1073.
12. Bolton S.J., Anthony D.C., Perry V.H. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience 1998, 86:1245-1257.
13. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J., VIGOR Study Group Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine 2000, 343. 1520-8, 2 p following 1528.
14. Bonmann E., Suschek C., Spranger M., Kolb-Bachofen V. The dominant role of exogenous or endogenous interleukin-1 beta on expression and activity of inducible nitric oxide synthase in rat microvascular brain endothelial cells. Neuroscience Letters 1997, 230:109-112.
15. Bourdon K.H., Rae D.S., Locke B.Z., Narrow W.E., Regier D.A. Estimating the prevalence of mental disorders in U.S. adults from the Epidemiologic Catchment Area Survey. Public Health Reports 1992, 107:663-668.
16. Bove K., Neumann P., Gertzberg N., Johnson A. Role of ecNOS-derived NO in mediating TNF-induced endothelial barrier dysfunction. American Journal of Physiology: Lung Cellular and Molecular Physiology 2001, 280:L914-L922.
17. Bozkurt B., Torre-Amione G., Warren M.S., Whitmore J., Soran O.Z., Feldman A.M., Mann D.L. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001, 103:1044-1047.
18. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., Baron J.A., Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine 2005, 352:1092-1102.
19. Brown A.D., Barton D.A., Lambert G.W. Cardiovascular abnormalities in patients with major depressive disorder: autonomic mechanisms and implications for treatment. CNS Drugs 2009, 23:583-602.
20. Brown E.S., Khan D.A., Nejtek V.A. The psychiatric side effects of corticosteroids. Annals of Allergy, Asthma and Immunology 1999, 83. 495-503; quiz 503-504.
21. Brustolim D., Ribeiro-dos-Santos R., Kast R.E., Altschuler E.L., Soares M.B. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. International Immunopharmacology 2006, 6:903-907.
22. Bush D.E., Ziegelstein R.C., Patel U.V., Thombs B.D., Ford D.E., Fauerbach J.A., McCann U.D., Stewart K.J., Tsilidis K.K., Patel A.L., Feuerstein C.J., Bass E.B. Post-myocardial infarction depression. Evidence Report: Technology Assessment (Summary) 2005, 123:1-8.
23. Candelario-Jalil E., Taheri S., Yang Y., Sood R., Grossetete M., Estrada E.Y., Fiebich B.L., Rosenberg G.A. Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. Journal of Pharmacology and Experimental Therapeutics 2007, 323:488-498.
24. Carney R.M., Blumenthal J.A., Stein P.K., Watkins L., Catellier D., Berkman L.F., Czajkowski S.M., O'Connor C., Stone P.H., Freedland K.E. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001, 104:2024-2028.
25. Carney R.M., Freedland K.E. Depression, mortality, and medical morbidity in patients with coronary heart disease. Biological Psychiatry 2003, 54:241-247.
26. Casolini P., Catalani A., Zuena A.R., Angelucci L. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. Journal of Neuroscience Research 2002, 68:337-343.
27. Cipollone F., Fazia M.L., Iezzi A., Cuccurullo C., De Cesare D., Ucchino S., Spigonardo F., Marchetti A., Buttitta F., Paloscia L., Mascellanti M., Cuccurullo F., Mezzetti A. Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. Arteriosclerosis, Thrombosis, and Vascular Biology 2005, 25:1925-1931.
28. Cohen H.W., Gibson G., Alderman M.H. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. American Journal of Medicine 2000, 108:2-8.
29. Collantes-Estevez E., Fernandez-Perez C. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. Current Medical Research and Opinion 2003, 19:402-410.
30. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nature Reviews Neuroscience 2008, 9:46-56.
31. Davis A., Gilhooley M., Agius M. Using non-steroidal anti-inflammatory drugs in the treatment of depression. Psychiatr. Danub 2010, 22(Suppl. 1):S49-S52.
32. de Jonge P., Spijkerman T.A., van den Brink R.H., Ormel J. Depression after myocardial infarction is a risk factor for declining health related quality of life and increased disability and cardiac complaints at 12 months. Heart 2006, 92:32-39.
33. de Vries H.E., Blom-Roosemalen M.C., van Oosten M., de Boer A.G., van Berkel T.J., Breimer D.D., Kuiper J. The influence of cytokines on the integrity of the blood-brain barrier in vitro. Journal of Neuroimmunology 1996, 64:37-43.
34. Defazio G., Trojano M., Ribatti D., Nico B., Giorelli M., De Salvia R., Russo G., Roncali L., Livrea P. ICAM 1 expression and fluid phase endocytosis of cultured brain microvascular endothelial cells following exposure to interferon beta-1a and TNFalpha. Journal of Neuroimmunology 1998, 88:13-20.
35. Descamps L., Cecchelli R., Torpier G. Effects of tumor necrosis factor on receptor-mediated endocytosis and barrier functions of bovine brain capillary endothelial cell monolayers. Journal of Neuroimmunology 1997, 74:173-184.
36. Deswal A., Bozkurt B., Seta Y., Parilti-Eiswirth S., Hayes F.A., Blosch C., Mann D.L. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999, 99:3224-3226.
37. Dickstein J.B., Moldofsky H., Hay J.B. Brain-blood permeability: TNF-alpha promotes escape of protein tracer from CSF to blood. American Journal of Physiology: Regulatory, Integrative, and Comparative Physiology 2000, 279:R148-R151.
38. Doyle F., McGee H.M., Conroy R.M., Delaney M. What predicts depression in cardiac patients: sociodemographic factors, disease severity or theoretical vulnerabilities?. Psychology Health 2011, 26:619-634.
39. Durieu-Trautmann O., Federici C., Creminon C., Foignant-Chaverot N., Roux F., Claire M., Strosberg A.D., Couraud P.O. Nitric oxide and endothelin secretion by brain microvessel endothelial cells: regulation by cyclic nucleotides. Journal of Cellular Physiology 1993, 155:104-111.
40. Elovaara I., Ukkonen M., Leppakynnas M., Lehtimaki T., Luomala M., Peltola J., Dastidar P. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Archives of Neurology 2000, 57:546-551.
41. Entman M.L., Michael L., Rossen R.D., Dreyer W.J., Anderson D.C., Taylor A.A., Smith C.W. Inflammation in the course of early myocardial ischemia. FASEB Journal 1991, 5:2529-2537.
42. Ertenli I., Ozer S., Kiraz S., Apras S.B., Akdogan A., Karadag O., Calguneri M., Kalyoncu U. Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatology International 2012, 32:323-330.
43. Feinstein D.L., Galea E., Roberts S., Berquist H., Wang H., Reis D.J. Induction of nitric oxide synthase in rat C6 glioma cells. Journal of Neurochemistry 1994, 62:315-321.
44. Felder R.B., Francis J., Zhang Z.H., Wei S.G., Weiss R.M., Johnson A.K. Heart failure and the brain: new perspectives. American Journal of Physiology: Regulatory, Integrative, and Comparative Physiology 2003, 284:R259-R276.
45. Fichtlscherer S., Rossig L., Breuer S., Vasa M., Dimmeler S., Zeiher A.M. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001, 104:3023-3025.
46. Fischer R., Maier O., Siegemund M., Wajant H., Scheurich P., Pfizenmaier K. A TNF receptor 2 selective agonist rescues human neurons from oxidative stress-induced cell death. PLoS One 2011, 6:e27621.
47. Fontaine V., Mohand-Said S., Hanoteau N., Fuchs C., Pfizenmaier K., Eisel U. Neurodegenerative and neuroprotective effects of tumor Necrosis factor (TNF) in retinal ischemia: opposite roles of TNF receptor 1 and TNF receptor 2. Journal of Neuroscience 2002, 22:RC216.
48. Francis J., Chu Y., Johnson A.K., Weiss R.M., Felder R.B. Acute myocardial infarction induces hypothalamic cytokine synthesis. American Journal of Physiology: Heart and Circulatory Physiology 2004, 286:H2264-H2271.
49. Francis J., Weiss R.M., Johnson A.K., Felder R.B. Central mineralocorticoid receptor blockade decreases plasma TNF-alpha after coronary artery ligation in rats. American Journal of Physiology: Regulatory, Integrative, and Comparative Physiology 2003, 284:R328-R335.
50. Frangogiannis N.G. The mechanistic basis of infarct healing. Antioxidants and Redox Signalling 2006, 8:1907-1939.
51. Frangogiannis N.G., Mendoza L.H., Lindsey M.L., Ballantyne C.M., Michael L.H., Smith C.W., Entman M.L. IL-10 is induced in the reperfused myocardium and may modulate the reaction to injury. Journal of Immunology 2000, 165:2798-2808.
52. Frasure-Smith N., Lesperance F., Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993, 270:1819-1825.
53. Fukuda S., Fini C.A., Mabuchi T., Koziol J.A., Eggleston L.L., del Zoppo G.J. Focal cerebral ischemia induces active proteases that degrade microvascular matrix. Stroke 2004, 35:998-1004.
54. Gelati M., Corsini E., Dufour A., Massa G., Giombini S., Solero C.L., Salmaggi A. High-dose methylprednisolone reduces cytokine-induced adhesion molecules on human brain endothelium. Canadian Journal of Neurological Sciences 2000, 27:241-244.
55. Glassman A.H., O'Connor C.M., Califf R.M., Swedberg K., Schwartz P., Bigger J.T., Krishnan K.R., van Zyl L.T., Swenson J.R., Finkel M.S., Landau C., Shapiro P.A., Pepine C.J., Mardekian J., Harrison W.M., Barton D., Mclvor M., Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002, 288:701-709.
56. Gluszko P., Bielinska A. Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors?. Polskie Archiwum Medycyny Wewnetrznej 2009, 119:231-235.
57. Goldston K., Baillie A.J. Depression and coronary heart disease: a review of the epidemiological evidence, explanatory mechanisms and management approaches. Clinical Psychology Review 2008, 28:288-306.
58. Greenberg J.D., Kremer J.M., Curtis J.R., Hochberg M.C., Reed G., Tsao P., Farkouh M.E., Nasir A., Setoguchi S., Solomon D.H., CORRONA Investigators Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2011, 70:576-582.
59. Greenhoot J.H., Reichenbach D.D. Cardiac injury and subarachnoid hemorrhage. A clinical, pathological, and physiological correlation. Journal of Neurosurgery 1969, 30:521-531.
60. Grippo A.J., Francis J., Weiss R.M., Felder R.B., Johnson A.K. Cytokine mediation of experimental heart failure-induced anhedonia. American Journal of Physiology: Regulatory, Integrative, and Comparative Physiology 2003, 284:R666-R673.
61. Grippo A.J., Johnson A.K. Biological mechanisms in the relationship between depression and heart disease. Neuroscience and Biobehavioral Reviews 2002, 26:941-962.
62. Gross S.S., Jaffe E.A., Levi R., Kilbourn R.G. Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochemical and Biophysical Research Communications 1991, 178:823-829.
63. Guck T.P., Kavan M.G., Elsasser G.N., Barone E.J. Assessment and treatment of depression following myocardial infarction. American Family Physician 2001, 64:641-648.
64. Guggilam A., Haque M., Kerut E.K., McIlwain E., Lucchesi P., Seghal I., Francis J. TNF-alpha blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats. American Journal of Physiology: Heart and Circulatory Physiology 2007, 293:H599-H609.
65. Hamann G.F., Okada Y., Fitridge R., del Zoppo G.J. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 1995, 26:2120-2126.
66. Hansen P.R., Svendsen J.H., Hoyer S., Kharazmi A., Bendtzen K., Haunso S. Tumor necrosis factor-alpha increases myocardial microvascular transport in vivo. American Journal of Physiology 1994, 266:H60-H67.
67. Henry C.B., Duling B.R. TNF-alpha increases entry of macromolecules into luminal endothelial cell glycocalyx. American Journal of Physiology: Heart and Circulatory Physiology 2000, 279:H2815-H2823.
68. Honig A., Lousberg R., Wojciechowski F.L., Cheriex E.C., Wellens H.J., van Praag H.M. Depression following a first heart infarct; similarities with and differences from 'ordinary' depression. Nederlands Tijdschrift Voor Geneeskunde 1997, 141:196-199.
69. Hu F., Wang X., Pace T.W., Wu H., Miller A.H. Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function. Molecular Psychiatry 2005, 10:426-428.
70. Hurst R.D., Clark J.B. Nitric oxide-induced blood-brain barrier dysfunction is not mediated by inhibition of mitochondrial respiratory chain activity and/or energy depletion. Nitric Oxide 1997, 1:121-129.
71. Hurst R.D., Fritz I.B. Nitric oxide-induced perturbations in a cell culture model of the blood-brain barrier. Journal of Cellular Physiology 1996, 167:89-94.
72. Huynh H.K., Dorovini-Zis K. Effects of interferon-gamma on primary cultures of human brain microvessel endothelial cells. American Journal of Pathology 1993, 142:1265-1278.
73. Kaloustian S., Bah T.M., Rondeau I., Mathieu S., Lada-Moldovan L., Ryvlin P., Godbout R., Rousseau G. Tumor necrosis factor-alpha participates in apoptosis in the limbic system after myocardial infarction. Apoptosis 2009, 14:1308-1316.
74. Kang Y.M., Zhang Z.H., Johnson R.F., Yu Y., Beltz T., Johnson A.K., Weiss R.M., Felder R.B. Novel effect of mineralocorticoid receptor antagonism to reduce proinflammatory cytokines and hypothalamic activation in rats with ischemia-induced heart failure. Circulation Research 2006, 99:758-766.
75. Kessler R.C. Epidemiology of women and depression. Journal of Affective Disorders 2003, 74:5-13.
76. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S., National Comorbidity Survey Replication The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105.
77. Kessler R.C., McGonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., Wittchen H.U., Kendler K.S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry 1994, 51:8-19.
78. Kloner R.A., Fishbein M.C., Lew H., Maroko P.R., Braunwald E. Mummification of the infarcted myocardium by high dose corticosteroids. Circulation 1978, 57:56-63.
79. Kosonen O., Kankaanranta H., Malo-Ranta U., Moilanen E. Nitric oxide-releasing compounds inhibit neutrophil adhesion to endothelial cells. European Journal of Pharmacology 1999, 382:111-117.
80. Krantz D.S., Whittaker K.S., Francis J.L., Rutledge T., Johnson B.D., Barrow G., McClure C., Sheps D.S., York K., Cornell C., Bittner V., Vaccarino V., Eteiba W., Parashar S., Vido D.A., Merz C.N. Psychotropic medication use and risk of adverse cardiovascular events in women with suspected coronary artery disease: outcomes from the Women's Ischemia Syndrome Evaluation (WISE) study. Heart 2009, 95:1901-1906.
81. Leenen F.H. Brain mechanisms contributing to sympathetic hyperactivity and heart failure. Circulation Research 2007, 101:221-223.
82. Lesperance F., Frasure-Smith N. Depression in patients with cardiac disease: a practical review. Journal of Psychosomatic Research 2000, 48:379-391.
83. Lesperance F., Frasure-Smith N., Koszycki D., Laliberte M.A., van Zyl L.T., Baker B., Swenson J.R., Ghatavi K., Abramson B.L., Dorian P., Guertin M.C., CREATE Investigators Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007, 297:367-379.
84. Lesperance F., Frasure-Smith N., Talajic M., Bourassa M.G. Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation 2002, 105:1049-1053.
85. Leussink V.I., Jung S., Merschdorf U., Toyka K.V., Gold R. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Archives of Neurology 2001, 58:91-97.
86. Li Y.F., Patel K.P. Paraventricular nucleus of the hypothalamus and elevated sympathetic activity in heart failure: the altered inhibitory mechanisms. Acta Physiologica Scandinavica 2003, 177:17-26.
87. Libby P., Maroko P.R., Bloor C.M., Sobel B.E., Braunwald E. Reduction of experimental myocardial infarct size by corticosteroid administration. Journal of Clinical Investigation 1973, 52:599-607.
88. Lichtman J.H., Bigger J.T., Blumenthal J.A., Frasure-Smith N., Kaufmann P.G., Lesperance F., Mark D.B., Sheps D.S., Taylor C.B., Froelicher E.S., American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Epidemiology and Prevention, American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research, American Psychiatric Association Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008, 118:1768-1775.
89. Lin P.Y., Su K.P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. Journal of Clinical Psychiatry 2007, 68:1056-1061.
90. Lippi G., Montagnana M., Favaloro E.J., Franchini M. Mental depression and cardiovascular disease: a multifaceted, bidirectional association. Seminars in Thrombosis and Hemostasis 2009, 35:325-336.
91. Lissoni P., Pelizzoni F., Mauri O., Perego M., Pittalis S., Barni S. Enhanced secretion of tumour necrosis factor in patients with myocardial infarction. European Journal of Medicine 1992, 1:277-280.
92. Ljung L., Simard J.F., Jacobsson L., Rantapaa-Dahlqvist S., Askling J., Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis and Rheumatism 2012, 64:42-52.
93. Lou J., Chofflon M., Juillard C., Donati Y., Mili N., Siegrist C.A., Grau G.E. Brain microvascular endothelial cells and leukocytes derived from patients with multiple sclerosis exhibit increased adhesion capacity. Neuroreport 1997, 8:629-633.
94. Luiten P.G., ter Horst G.J., Karst H., Steffens A.B. The course of paraventricular hypothalamic efferents to autonomic structures in medulla and spinal cord. Brain Research 1985, 329:374-378.
95. Maas D.W., Westendorp R.G., Willems J.M., de Craen A.J., van der Mast R.C. TNF-alpha antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial. Journal of Clinical Psychopharmacology 2010, 30:343-345.
96. Maeland J.G., Havik O.E. Psychological predictors for return to work after a myocardial infarction. Journal of Psychosomatic Research 1987, 31:471-481.
97. Man S., Ubogu E.E., Ransohoff R.M. Inflammatory cell migration into the central nervous system: a few new twists on an old tale. Brain Pathology 2007, 17:243-250.
98. Mann D.L., McMurray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S., Djian J., Drexler H., Feldman A., Kober L., Krum H., Liu P., Nieminen M., Tavazzi L., van Veldhuisen D.J., Waldenstrom A., Warren M., Westheim A., Zannad F., Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
99. Marchetti L., Klein M., Schlett K., Pfizenmaier K., Eisel U.L. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-d-aspartate receptor activation, Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. Journal of Biological Chemistry 2004, 279:32869-32881.
100. Mark K.S., Miller D.W. Increased permeability of primary cultured brain microvessel endothelial cell monolayers following TNF-alpha exposure. Life Sciences 1999, 64:1941-1953.
101. Mark K.S., Trickler W.J., Miller D.W. Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. Journal of Pharmacology and Experimental Therapeutics 2001, 297:1051-1058.
102. Mayhan W.G. Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier. Brain Research 2002, 927:144-152.
103. Megyeri P., Abraham C.S., Temesvari P., Kovacs J., Vas T., Speer C.P. Recombinant human tumor necrosis factor alpha constricts pial arterioles and increases blood-brain barrier permeability in newborn piglets. Neuroscience Letters 1992, 148:137-140.
104. Meijer A., Conradi H.J., Bos E.H., Thombs B.D., van Melle J.P., de Jonge P. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis of 25 years of research. General Hospital Psychiatry 2011, 33:203-216.
105. Miyaoka T., Wake R., Furuya M., Liaury K., Ieda M., Kawakami K., Tsuchie K., Taki M., Ishihara K., Araki T., Horiguchi J. Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2012, 37:222-226.
106. Monden Y., Kubota T., Inoue T., Tsutsumi T., Kawano S., Ide T., Tsutsui H., Sunagawa K. Tumor necrosis factor-alpha is toxic via receptor 1 and protective via receptor 2 in a murine model of myocardial infarction. American Journal of Physiology: Heart and Circulatory Physiology 2007, 293:H743-H753.
107. Muller N., Myint A.M., Schwarz M.J. Inflammatory biomarkers and depression. Neurotoxicity Research 2011, 19:308-318.
108. Muller N., Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Molecular Psychiatry 2007, 12:988-1000.
109. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Moller H.J., Arolt V., Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Molecular Psychiatry 2006, 11:680-684.
110. Musselman D.L., Evans D.L., Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Archives of General Psychiatry 1998, 55:580-592.
111. Nakada M.T., Tam S.H., Woulfe D.S., Casper K.A., Swerlick R.A., Ghrayeb J. Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells. Cell Adhesion and Communication 1998, 5:491-503.
112. National Collaborating Centre for Mental Health Depression in Adults (update). Depression: The Treatment and Management of Depression in Adults 2009, National Institute for Health and Clinical Excellence (NICE), London.
113. Palmer R.M., Bridge L., Foxwell N.A., Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. British Journal of Pharmacology 1992, 105:11-12.
114. Pavlovic S., Du B., Sakamoto K., Khan K.M., Natarajan C., Breyer R.M., Dannenberg A.J., Falcone D.J. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. Journal of Biological Chemistry 2006, 281:3321-3328.
115. Payne D.K., Fuseler J.W., Owens M.W. Modulation of endothelial cell permeability by lung carcinoma cells: a potential mechanism of malignant pleural effusion formation. Inflammation 1994, 18:407-417.
116. Pereira V.H., Cerqueira J.J., Palha J.A., Sousa N. Stressed brain, diseased heart: a review on the pathophysiologic mechanisms of neurocardiology. International Journal of Cardiology 2012.
117. Perry V.H., Anthony D.C., Bolton S.J., Brown H.C. The blood-brain barrier and the inflammatory response. Molecular Medicine Today 1997, 3:335-341.
118. Petito C.K., Adkins B., Tracey K., Roberts B., Torres-Munoz J., McCarthy M., Czeisler C. Chronic systemic administration of tumor necrosis factor alpha and HIV gp120: effects on adult rodent brain and blood-brain barrier. Journal of Neurovirology 1999, 5:314-318.
119. Pilote L., Dasgupta K., Guru V., Humphries K.H., McGrath J., Norris C., Rabi D., Tremblay J., Alamian A., Barnett T., Cox J., Ghali W.A., Grace S., Hamet P., Ho T., Kirkland S., Lambert M., Libersan D., O'Loughlin J., Paradis G., Petrovich M., Tagalakis V. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007, 176:S1-S44.
120. Poole L., Dickens C., Steptoe A. The puzzle of depression and acute coronary syndrome: reviewing the role of acute inflammation. Journal of Psychosomatic Research 2011, 71:61-68.
121. Pouget R., Yersin B., Wietlisbach V., Bumand B., Bula C.J. Depressed mood in a cohort of elderly medical inpatients: prevalence, clinical correlates and recognition rate. Aging 2000, 12:301-307.
122. Pretorius E. Corticosteroids, depression and the role of serotonin. Reviews in the Neurosciences 2004, 15:109-116.
123. Pryce G., Male D., Campbell I., Greenwood J. Factors controlling T-cell migration across rat cerebral endothelium in vitro. Journal of Neuroimmunology 1997, 75:84-94.
124. Raison C.L., Capuron L., Miller A.H. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends in Immunology 2006, 27:24-31.
125. Ramani R., Mathier M., Wang P., Gibson G., Togel S., Dawson J., Bauer A., Alber S., Watkins S.C., McTiernan C.F., Feldman A.M. Inhibition of tumor necrosis factor receptor-1-mediated pathways has beneficial effects in a murine model of postischemic remodeling. American Journal of Physiology: Heart and Circulatory Physiology 2004, 287:H1369-H1377.
126. Rana I., Stebbing M., Kompa A., Kelly D.J., Krum H., Badoer E. Microglia activation in the hypothalamic PVN following myocardial infarction. Brain Research 2010, 1326:96-104.
127. Reiss Y., Hoch G., Deutsch U., Engelhardt B. T cell interaction with ICAM-1-deficient endothelium in vitro: essential role for ICAM-1 and ICAM-2 in transendothelial migration of T cells. European Journal of Immunology 1998, 28:3086-3099.
128. Richard V., Murry C.E., Reimer K.A. Healing of myocardial infarcts in dogs. Effects of late reperfusion. Circulation 1995, 92:1891-1901.
129. Roberts R., DeMello V., Sobel B.E. Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation 1976, 53:I204-I206.
130. Rosenberg G.A., Estrada E.Y., Dencoff J.E., Stetler-Stevenson W.G. Tumor necrosis factor-alpha-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Research 1995, 703:151-155.
131. Rugulies R. Depression as a predictor for coronary heart disease. A review and meta-analysis. American Journal of Preventive Medicine 2002, 23:51-61.
132. Saija A., Princi P., Lanza M., Scalese M., Aramnejad E., De Sarro A. Systemic cytokine administration can affect blood-brain barrier permeability in the rat. Life Sciences 1995, 56:775-784.
133. Sandrini M., Vitale G., Pini L.A. Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflammation Research 2002, 51:154-159.
134. Savitz J., Preskorn S., Teague T.K., Drevets D., Yates W., Drevets W. Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2×2 clinical trial. BMJ Open 2012, 2:e000643.
135. Schleifer S.J., Macari-Hinson M.M., Coyle D.A., Slater W.R., Kahn M., Gorlin R., Zucker H.D. The nature and course of depression following myocardial infarction. Archives of Internal Medicine 1989, 149:1785-1789.
136. Schnell L., Fearn S., Schwab M.E., Perry V.H., Anthony D.C. Cytokine-induced acute inflammation in the brain and spinal cord. Journal of Neuropathology and Experimental Neurology 1999, 58:245-254.
137. Schulz R., Heusch G. Tumor necrosis factor-alpha and its receptors 1 and 2: Yin and Yang in myocardial infarction?. Circulation 2009, 119:1355-1357.
138. Seguin R., Biernacki K., Rotondo R.L., Prat A., Antel J.P. Regulation and functional effects of monocyte migration across human brain-derived endothelial cells. Journal of Neuropathology and Experimental Neurology 2003, 62:412-419.
139. Serrano C.V., Setani K.T., Sakamoto E., Andrei A.M., Fraguas R. Association between depression and development of coronary artery disease: pathophysiologic and diagnostic implications. Journal of Vascular Health and Risk Management 2011, 7:159-164.
140. Sherwood A., Blumenthal J.A., Trivedi R., Johnson K.S., O'Connor C.M., Adams K.F., Dupree C.S., Waugh R.A., Bensimhon D.R., Gaulden L., Christenson R.H., Koch G.G., Hinderliter A.L. Relationship of depression to death or hospitalization in patients with heart failure. Archives of Internal Medicine 2007, 167:367-373.
141. Siepmann M., Grossmann J., Muck-Weymann M., Kirch W. Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Psychopharmacology 2003, 168:293-298.
142. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., Geis G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000, 284:1247-1255.
143. Silverstone P.H., Lemay T., Elliott J., Hsu V., Starko R. The prevalence of major depressive disorder and low self-esteem in medical inpatients. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 1996, 41:67-74.
144. Simmons M.L., Murphy S. Induction of nitric oxide synthase in glial cells. Journal of Neurochemistry 1992, 59:897-905.
145. Sluiter W., Pietersma A., Lamers J.M., Koster J.F. Leukocyte adhesion molecules on the vascular endothelium: their role in the pathogenesis of cardiovascular disease and the mechanisms underlying their expression. Journal of Cardiovascular Pharmacology 1993, 22(Suppl. 4):S37-S44.
146. Staykova M., Maxwell L., Willenborg D. Kinetics and polarization of the membrane expression of cytokine-induced ICAM-1 on rat brain endothelial cells. Journal of Neuropathology and Experimental Neurology 2000, 59:120-128.
147. Strik J.J., Honig A., Maes M. Depression and myocardial infarction: relationship between heart and mind. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2001, 25:879-892.
148. Sun M., Dawood F., Wen W.H., Chen M., Dixon I., Kirshenbaum L.A., Liu P.P. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 2004, 110:3221-3228.
149. Ter Horst G.J., Van der Werf Y.D., De J.M.J.L. Acute myocardial infarction and cytokine-mediated selective blood-brain barrier leakage in the rat. Journal of Neurochemistry 1996, 66(Suppl. 2):S54.
150. Ter Horst G.J., Nagel J.G., De Jongste M.J.L., Van der Werf Y.D. Selective blood-brain barrier dysfunction after intravenous injections of rTNFa in the rat. Neurochemistry: Cellular, Molecular and Clinical Aspects 1997, 141-146. Plenum, New York. A. Teelken, J. Korf (Eds.).
151. Thombs B.D., Bass E.B., Ford D.E., Stewart K.J., Tsilidis K.K., Patel U., Fauerbach J.A., Bush D.E., Ziegelstein R.C. Prevalence of depression in survivors of acute myocardial infarction. Journal of General Internal Medicine 2006, 21:30-38.
152. Thombs B.D., de Jonge P., Coyne J.C., Whooley M.A., Frasure-Smith N., Mitchell A.J., Zuidersma M., Eze-Nliam C., Lima B.B., Smith C.G., Soderlund K., Ziegelstein R.C. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA 2008, 300:2161-2171.
153. Trickler W.J., Mayhan W.G., Miller D.W. Brain microvessel endothelial cell responses to tumor necrosis factor-alpha involve a nuclear factor kappa B (NF-kappaB) signal transduction pathway. Brain Research 2005, 1048:24-31.
154. Tulner D.M., Smith O.R., Schins A., de Jonge P., Quere M., Delanghe J.R., Crijns H.J., den Boer J.A., Korf J., Honig A. Antidepressive effect of mirtazapine in post-myocardial infarction depression is associated with soluble TNF-R1 increase: data from the MIND-IT. Neuropsychobiology 2011, 63:169-176.
155. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
156. Uher R., Carver S., Power R.A., Mors O., Maier W., Rietschel M., Hauser J., Dernovsek M.Z., Henigsberg N., Souery D., Placentino A., Farmer A., McGuffin P. Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychological Medicine 2012, 1-9.
157. Van der Werf Y.D., De Jongste M.J.L., Ter Horst G.J. The immune system mediates blood-brain barrier damage: possible implications for pathophysiology of neuropsychiatric illnesses. Acta Neuropsychiat 1995, 7:114-121.
158. van Melle J.P., de Jonge P., Honig A., Schene A.H., Kuyper A.M., Crijns H.J., Schins A., Tulner D., van den Berg M.P., Ormel J., MIND-IT investigators Effects of antidepressant treatment following myocardial infarction. British Journal of Psychiatry 2007, 190:460-466.
159. van Zyl L.T., Lesperance F., Frasure-Smith N., Malinin A.I., Atar D., Laliberte M.A., Serebruany V.L. Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. Journal of Thrombosis and Thrombolysis 2009, 27:48-56.
160. Wang J.T., Hoffman B., Blumenthal J.A. Management of depression in patients with coronary heart disease: association, mechanisms, and treatment implications for depressed cardiac patients. Expert Opinion on Pharmacotherapy 2011, 12:85-98.
161. Warner-Schmidt J.L., Vanover K.E., Chen E.Y., Marshall J.J., Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:9262-9267.
162. Weber C., Erl W., Pietsch A., Weber P.C. Aspirin inhibits nuclear factor-kappa B mobilization and monocyte adhesion in stimulated human endothelial cells. Circulation 1995, 91:1914-1917.
163. Wong D., Dorovini-Zis K. Expression of vascular cell adhesion molecule-1 (VCAM-1) by human brain microvessel endothelial cells in primary culture. Microvascular Research 1995, 49:325-339.
164. Wong D., Prameya R., Dorovini-Zis K. In vitro adhesion and migration of T lymphocytes across monolayers of human brain microvessel endothelial cells: regulation by ICAM-1, VCAM-1, E-selectin and PECAM-1. Journal of Neuropathology and Experimental Neurology 1999, 58:138-152.
165. Xiong G.L., Jiang W., Clare R., Shaw L.K., Smith P.K., Mahaffey K.W., O'Connor C.M., Krishnan K.R., Newby L.K. Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. American Journal of Cardiology 2006, 98:42-47.
166. Yang Y., Estrada E.Y., Thompson J.F., Liu W., Rosenberg G.A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. Journal of Cerebral Blood Flow and Metabolism 2007, 27:697-709.
167. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
168. Yu Y., Zhang Z.H., Wei S.G., Serrats J., Weiss R.M., Felder R.B. Brain perivascular macrophages and the sympathetic response to inflammation in rats after myocardial infarction. Hypertension 2010, 55:652-659.
169. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L., INTERHEART Study Investigators Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
170. Zettlitz K.A., Lorenz V., Landauer K., Munkel S., Herrmann A., Scheurich P., Pfizenmaier K., Kontermann R. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs 2010, 2:639-647.
171. Ziegelstein R.C., Fauerbach J.A., Stevens S.S., Romanelli J., Richter D.P., Bush D.E. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Archives of Internal Medicine 2000, 160:1818-1823.